Acute Myeloid Leukemia Market Analysis, Share And Growth 2025 To 2034

By combining trend forecasting and competitive intelligence, this report supports future-focused strategy in the acute myeloid leukemia sector.

What Is The Projected Market Size & Growth Rate Of The Acute Myeloid Leukemia Market?
The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growth aging population, environmental factors, genetic predisposition, limited treatment options, medical advancements.

The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing advancements in targeted therapies, immunotherapies development, precision medicine approaches, increased awareness and early detection, collaborative research initiatives. Major trends in the forecast period include emphasis on minimal residual disease monitoring, integration of artificial intelligence (AI) in treatment decision support, focus on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, patient advocacy and empowerment programs.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp

What Is The Crucial Factor Driving The Global Acute Myeloid Leukemia Market?
The increase in the older population base and growing unmet healthcare needs is expected to propel the growth of the acute myeloid leukemia market over the coming years. The geriatric population and growing unmet healthcare are defined as the elderly population, people aged 65 and over suffering from health issues like acute myeloid leukemia. For instance, according to the American Cancer Society USA (ACS), a nationwide voluntary health organization, in 2022, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low. It affected approximately 60,650 people in 2022 and caused 24000 deaths. Therefore, the geriatric population base and growing unmet healthcare needs drive the gelatin market.

Segment Covered In The Acute Myeloid Leukemia Market Report
The acute myeloid leukemiamarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Radiation therapy; Stem Cell Transplant; Targeted Therapy
2) By Chemotherapy: Cytarabine; Anthracycline Drugs; Alkylating Agents; Anti-metabolites; Tyrosine Kinase Inhibitors; Hormonal Therapy
3) By Regimen: DC Regimen; AVD Regimen; VCD Regimen
4) By End-User: Hospital; Retails Drug Stores; Ambulatory Care Centers; Clinics

Subsegments:
1) By Chemotherapy: Induction Chemotherapy; Consolidation Chemotherapy
2) By Radiation Therapy: Total Body Irradiation; Localized Radiation Therapy
3) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
4) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Other Targeted Agents

Key Trends Driving Growth In The Acute Myeloid Leukemia Market
Growing investments in R&D using the pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market. R&D is used to develop new and improved products and services to fulfill the needs of drug development. For instance, in May 2022, according to National Library of Medicine, a US-based national medical library, a study with the title ‘Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ is in Phase III of clinical trials. It commenced in November 2021 and is expected to conclude by March 2025.

Key Player In The Acute Myeloid Leukemia Market
Major companies operating in the acute myeloid leukemia market include Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.

View the full acute myeloid leukemia market report here:
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Global Acute Myeloid Leukemia Market - Regional Insights:
North America was the largest region in the acute myeloid leukemia market in 2024. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company